Table 1.
Comparsion between the two groups of patients tested for either QFT-G or T-SPOT.TB
| QFT-G | T-SPOT.TB | ||
|---|---|---|---|
| (n=169) | (n=43) | P value | |
| n(%)* | n(%)* | ||
| T-SPOT.TB/QFT-G results | 0.004 | ||
| Positive | 119 (70.4) | 40 (93) | |
| Negative | 50 (29.6) | 3 (7) | |
| Sociodemographics | |||
| Country of enrollment | 0.03 | ||
| Mexico-Tamaulipas | 130 (76.9) | 26 (60.5) | |
| US-Texas | 39 (23.1) | 17 (39.5) | |
| BCG vaccination | 0.09 | ||
| Yes | 114 (74.5) | 35 (87.5) | |
| No | 39 (25.5) | 5 (12.5) | |
| White Hispanic | 168 (99.4) | 43 (100) | 1.00 |
| Age | 0.50 | ||
| 20–35 | 62 (36.7) | 16 (37.2) | |
| 36–59 | 83 (49.1) | 18 (41.9) | |
| 60+ | 24 (14.2) | 9 (20.9) | |
| Gender | 0.77 | ||
| Male | 114 (67.5) | 28 (65.1) | |
| Female | 55 (32.5) | 15 (34.9) | |
| TB characteristics at enrollment | |||
| Smear result | 0.44 | ||
| Positive | 154 (91.7) | 36 (87.8) | |
| Negative | 14 (8.3) | 5 (12.2) | |
| Culture performed | 0.06 | ||
| Yes | 84 (50.3) | 29 (67.4) | |
| No | 83 (49.7) | 14 (32.6) | |
| Days of anti-TB treatment | <0.001 | ||
| None | 42 (24.9) | 28 (65.1) | |
| Between 1 and 7 | 127 (75.1) | 15 (34.9) | |
| Diabetes and body-mass index | |||
| Diabetes | 0.14 | ||
| Yes | 73 (43.2) | 24 (55.8) | |
| No | 96 (56.8) | 19 (44.2) | |
| HbA1c ≥ 6.5% | 0.10 | ||
| Yes | 56 (33.1) | 20 (46.5) | |
| No | 113 (66.9) | 23 (53.5) | |
| Hyperglycemia | 0.36 | ||
| Yes | 47 (27.8) | 15 (34.9) | |
| No | 122 (72.2) | 28 (65.1) | |
| Body mass index | 0.15 | ||
| Underweight | 33 (19.5) | 3 (7.1) | |
| Normal weight | 94 (55.6) | 26 (61.9) | |
| Overweight or obese | 42 (24.9) | 13 (31) | |
| Risks for TB other than diabetes | |||
| Alcohol abuse | 0.20 | ||
| Yes | 32 (18.9) | 12 (27.9) | |
| No | 137 (81.1) | 31 (72.1) | |
| Drug abuse | 0.002 | ||
| Yes | 39 (23.1) | 1 (2.4) | |
| No | 130 (76.9) | 41 (97.6) | |
| History of incarceration | 0.49 | ||
| Yes | 10 (5.9) | 4 (9.3) | |
| No | 159 (94.1) | 39 (90.7) | |
| HIV positive | 1.00 | ||
| Yes | 5 (3) | 1 (2.3) | |
| No | 164 (97) | 42 (97.7) | |
*
Due to missing demographic information (BCG vaccine, n=153 for QFT-G and n=40 for T-spot.TB; Smear, n=168 for QFT, n=41 for T-spot.TB; drug abuse, n=41 for T-spot.TB), totals will not sum to the total sample; QFT-G, QuantiFERON®-TB Gold; T-SPOT, T.SPOT®.TB